Gateway Analytical is proud to announce that we’ve been invited by a FDA representative to speak at the scientific program of the 27th Annual International Forum and Exhibition Process Analytical Technology…
This article provides an introduction to automated scanning electron microscopy—energy dispersive spectroscopy (SEM-EDS) and the capabilities it can offer in development of inhalable drug products. Case studies are presented…
Gateway Analytical announced today that the company will move to a larger facility at 5316 William Penn Highway, Gibsonia, Pa. after outgrowing the current laboratory and office space. In just…
Outsourcing the development and manufacturing of generic drug products is a very common strategy in today’s current global market. Because of this, some of the biggest generic manufacturers of…
PITTSBURGH, PA – Gateway Analytical announced today that the company received its 17025:2005 accreditation from the American Association for Laboratory Accreditation (A2LA). This accreditation is another illustration of Gateway’s commitment…
June 17, 2014 Since the approval of Dry Powder Inhalers containing Fluticasone Propionate and Salmeterol Xinafoate in 1999, combination inhaled therapies have dominated the COPD market. However, due to the lack of specific guidance of the Office of Generic Drugs as to the abbreviated new drug application submission, there was…
Recently we sat down with Emily Landsperger, Scientist II at Gateway Analytical, to discuss our new HIAC testing service for USP <788> and <789> Compliance. Read on to learn more about how Gateway…
Read Gateway Analytical's piece on shedding light on the utility of FTIR vs. Raman spectroscopy.